田文杰, 董鼎辉, 郝杰, 等. 原位肝移植术后胆道吻合口狭窄的综合微创治疗效果:单中心60例分析[J]. 器官移植, 2022, 13(5): 597-604. DOI: 10.3969/j.issn.1674-7445.2022.05.008
引用本文: 田文杰, 董鼎辉, 郝杰, 等. 原位肝移植术后胆道吻合口狭窄的综合微创治疗效果:单中心60例分析[J]. 器官移植, 2022, 13(5): 597-604. DOI: 10.3969/j.issn.1674-7445.2022.05.008
Tian Wenjie, Dong Dinghui, Hao Jie, et al. Comprehensive minimally invasive treatment for biliary anastomotic stenosis after orthotopic liver transplantation: a single center analysis of 60 cases[J]. ORGAN TRANSPLANTATION, 2022, 13(5): 597-604. DOI: 10.3969/j.issn.1674-7445.2022.05.008
Citation: Tian Wenjie, Dong Dinghui, Hao Jie, et al. Comprehensive minimally invasive treatment for biliary anastomotic stenosis after orthotopic liver transplantation: a single center analysis of 60 cases[J]. ORGAN TRANSPLANTATION, 2022, 13(5): 597-604. DOI: 10.3969/j.issn.1674-7445.2022.05.008

原位肝移植术后胆道吻合口狭窄的综合微创治疗效果:单中心60例分析

Comprehensive minimally invasive treatment for biliary anastomotic stenosis after orthotopic liver transplantation: a single center analysis of 60 cases

  • 摘要:
      目的  探讨以内镜逆行胆胰管造影术(ERCP)为主的综合微创方案治疗肝移植术后胆道吻合口狭窄(BAS)的临床效果。
      方法  回顾性分析60例肝移植术后BAS受者的资料,其中男54例,女6例,年龄(48±10)岁。首先采用ERCP治疗,成功后放置胆道塑料或金属支架,失败者选择经皮经肝胆道引流术(PTCD)会师法或经口单人操作胆道镜(SpyGlass)通过狭窄,以上均失败者则进行磁吻合再通法或其他特殊方法。总结肝移植术后BAS的发生及治疗情况,分析治疗结果、脱支架情况及复发情况。
      结果  肝移植术后发生BAS的中位时间为8(4,13)个月,术后1年内、1~2年及2年以上诊断BAS的受者分别为39例、16例及5例。60例肝移植术后BAS受者均得到成功救治,其中56例首先进行ERCP,41例完成BAS治疗,成功率为73%,导丝不能通过是ERCP失败的主要原因;PTCD、SpyGlass及磁吻合再通法的成功率分别为5/9、5/7及7/8;2例通过经皮胆道镜导丝钝头突破技术和胆道十二指肠内瘘口放置支架治疗成功。38例经过3(3,4)次ERCP、13(8,18)个月支架留置后达到脱支架标准,其中塑料支架25例,金属支架13例,塑料支架留置时间较金属支架长(P < 0.05)。6例在脱支架后12(8,33)个月狭窄复发,复发率为16%。复发者再次ERCP治疗,5例成功脱支架无复发。多因素分析结果提示狭窄诊断时间迟、脱支架前ERCP治疗次数多是BAS复发的独立危险因素(均为P < 0.05)。
      结论  以ERCP为主的综合微创方案可提高肝移植术后BAS治疗成功率,远期效果满意,BAS诊断时间迟、脱支架所需ERCP次数多是BAS复发的独立危险因素。

     

    Abstract:
      Objective  To evaluate the clinical efficacy of endoscopic retrograde cholangiopancreatography (ERCP)-based comprehensive minimally invasive treatment for biliary anastomotic stenosis (BAS) after liver transplantation.
      Methods  Clinical data of 60 BAS recipients after liver transplantation were retrospectively analyzed, 54 male and 6 female, aged (48±10) years. ERCP was initially carried out. If it succeeded, plastic or metallic stents were placed into the biliary tract. If it failed, percutaneous transhepatic cholangial drainage (PTCD) or single-operator cholangioscopy (SpyGlass) was adopted to pass through the stenosis. If all these procedures failed, magnetic anastomosis or other special methods were delivered. The incidence and treatment of BAS after liver transplantation were summarized. The efficacy, stent removal and recurrence were observed.
      Results  The median time of incidence of BAS after liver transplantation was 8 (4, 13) months. Within postoperative 1 year, 1-2 years and over 2 years, 39, 16 and 5 recipients were diagnosed with BAS, respectively. All 60 BAS recipients after liver transplantation were successfully treated, including 56 cases initially receiving ERCP, and 41 completing BAS treatment, with a success rate of 73%. The failure of guide wire was the main cause of ERCP failure. The success rates of PTCD, SpyGlass and magnetic anastomosis were 5/9, 5/7 and 7/8, respectively. Two recipients were successfully treated by percutaneous choledochoscope-assisted blunt guide wire technique and stent placement in the biliary and duodenal fistula. After 3 (3, 4) cycles of ERCP and 13 (8, 18) months of stent indwelling, 38 recipients reached the stent removal criteria, including 25 plastic stents and 13 metallic stents. The indwelling time of plastic stents was longer than that of metallic stents (P < 0.05). Six cases suffered from stenosis recurrence at 12 (8, 33) months after stent removal, and the recurrence rate was 16%. Six patients were treated with ERCP, and 5 of them did not recur after the stents were successfully removed. Multivariate analysis showed that delayed diagnosis of stenosis and frequent ERCP before stent removal were the independent risk factors for BAS recurrence (both P < 0.05).
      Conclusions  ERCP-based comprehensive minimally invasive treatment may improve the success rate of BAS treatment after liver transplantation and yield satisfactory long-term efficacy. Delayed diagnosis of BAS and high frequent ERCP required for stent removal are the independent risk factors for BAS recurrence.

     

/

返回文章
返回